losartan has been researched along with Muscle Contraction in 91 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Muscle Contraction: A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan is a Food and Drug Administration approved antihypertensive medication that is recently emerging as an antifibrotic therapy." | 5.40 | Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury. ( Corona, BT; Garg, K; Walters, TJ, 2014) |
| "Losartan has been proposed for the prevention of thoracic aortic aneurysm." | 5.35 | Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome. ( Chum, E; Chung, AW; Kim, JM; van Breemen, C; Yang, HH, 2009) |
| "This study was performed to investigate the roles of angiotensin receptors (AT1 and AT2) in the contractility of uterine arteries during normal pregnancy and after angiotensin II levels have been elevated." | 3.70 | Interactions between AT1 and AT2 receptors in uterine arteries from pregnant ewes. ( Burrell, JH; Gibson, KJ; Lumbers, ER; McMullen, JR; Wu, J, 1999) |
| "Adult male Sprague-Dawley rats were subjected to partial unilateral ureteral obstruction (UUO) and divided into two groups, that is, those treated with (group L, N = 21) and those without (group C, N = 21) an angiotensin type 1 (AT1) receptor antagonist (losartan)." | 3.70 | Salutary role for angiotensin in partial urinary tract obstruction. ( Fogo, AB; Fujinaka, H; Ichikawa, I; Inagami, T; Matsusaka, T; Miyazaki, Y; Yoshida, H, 2000) |
| " The renin-angiotensin system has been implicated in vascular and cardiac hypertrophy, but the involvement of angiotensin II (ANG II) as a trophic factor in the lower urinary tract has not been investigated." | 3.69 | Angiotensin II and bladder obstruction in the rat: influence on hypertrophic growth and contractility. ( Andersson, KE; Pandita, RK; Persson, K; Waldeck, K, 1996) |
| "Losartan treatment prevented these SAD-induced changes." | 1.48 | Effects of losartan on vasomotor function and canonical transient receptor potential channels in the aortas of sinoaortic denervation rats. ( Liang, M; Liu, Y; Miao, F; Wu, H; Zhong, W, 2018) |
| "Losartan is a Food and Drug Administration approved antihypertensive medication that is recently emerging as an antifibrotic therapy." | 1.40 | Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury. ( Corona, BT; Garg, K; Walters, TJ, 2014) |
| "Losartan has been proposed for the prevention of thoracic aortic aneurysm." | 1.35 | Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome. ( Chum, E; Chung, AW; Kim, JM; van Breemen, C; Yang, HH, 2009) |
| "Losartan treatments prevented EC training-induced increases in muscle wet and dry weights compared to untreated rats." | 1.33 | AT1 receptors are necessary for eccentric training-induced hypertrophy and strength gains in rat skeletal muscle. ( McBride, TA, 2006) |
| "Pretreatment with losartan (10(-8)-10(-5) mol/l) inhibited the contractile response of U46619 and shifted the concentration-response curve to the right in dose-dependent manner." | 1.30 | Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries. ( Brosnihan, KB; Ferrario, CM; Li, P, 1997) |
| "Losartan treatment resulted in a dose-dependent reduction in the media thickness and mediato-lumen ratio in small arteries from the four vascular beds studied on the wire myograph and in pressurized mesenteric small arteries." | 1.30 | Effect of AT1 angiotensin-receptor blockade on structure and function of small arteries in SHR. ( Li, JS; Schiffrin, EL; Sharifi, AM, 1997) |
| "In reserpine- and prazosin-treated anesthetized fowl, [Val5]ANG II caused dose-dependent vasodepressor actions inhibited by neither losartan (10 mg/kg) nor PD-123319 (10 mg/kg)." | 1.29 | Novel angiotensin receptor subtypes in fowl. ( Chiu, AT; Keiser, J; Madison, AB; Nishimura, H; Patton, CM; Walker, OE, 1994) |
| "Losartan at lower concentrations (3-100 nM) concentration dependently depressed the maximal responses to angiotensin II." | 1.29 | A non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations. ( Pfaffendorf, M; Van Zwieten, PA; Zhang, J; Zhang, JS, 1994) |
| " Losartan shifted the dose-response curve of angiotensin II to the right with a pA2 value of 8." | 1.29 | Characterization of contractile response to angiotensin in epididymal rat vas deferens. ( Cheung, WT; Sum, CS, 1995) |
| "Losartan was used as the reference compound." | 1.29 | Tranilast antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells. ( Fukuyama, J; Hamano, S; Misawa, K; Miyazawa, K; Ujiie, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 54 (59.34) | 18.2507 |
| 2000's | 23 (25.27) | 29.6817 |
| 2010's | 13 (14.29) | 24.3611 |
| 2020's | 1 (1.10) | 2.80 |
| Authors | Studies |
|---|---|
| Bühlmayer, P | 1 |
| Criscione, L | 1 |
| Fuhrer, W | 1 |
| Furet, P | 1 |
| de Gasparo, M | 1 |
| Stutz, S | 1 |
| Whitebread, S | 1 |
| Norman, MH | 1 |
| Smith, HD | 1 |
| Andrews, CW | 1 |
| Tang, FL | 1 |
| Cowan, CL | 1 |
| Steffen, RP | 1 |
| Sircar, I | 1 |
| Hodges, JC | 2 |
| Quin, J | 1 |
| Bunker, AM | 1 |
| Winters, RT | 1 |
| Edmunds, JJ | 1 |
| Kostlan, CR | 1 |
| Connolly, C | 1 |
| Kesten, SJ | 1 |
| Hamby, JM | 1 |
| Winn, M | 1 |
| De, B | 1 |
| Zydowsky, TM | 1 |
| Altenbach, RJ | 1 |
| Basha, FZ | 1 |
| Boyd, SA | 1 |
| Brune, ME | 1 |
| Buckner, SA | 1 |
| Crowell, D | 1 |
| Drizin, I | 1 |
| Schmidt, B | 1 |
| Lindman, S | 1 |
| Tong, W | 1 |
| Lindeberg, G | 1 |
| Gogoll, A | 1 |
| Lai, Z | 1 |
| Thörnwall, M | 1 |
| Synnergren, B | 1 |
| Nilsson, A | 1 |
| Welch, CJ | 1 |
| Sohtell, M | 1 |
| Westerlund, C | 1 |
| Nyberg, F | 1 |
| Karlén, A | 1 |
| Hallberg, A | 1 |
| Yamasaki, E | 1 |
| Thakore, P | 1 |
| Krishnan, V | 1 |
| Earley, S | 1 |
| Liang, M | 1 |
| Zhong, W | 1 |
| Miao, F | 1 |
| Wu, H | 1 |
| Liu, Y | 1 |
| Lino Cardenas, CL | 1 |
| Kessinger, CW | 1 |
| MacDonald, C | 1 |
| Jassar, AS | 1 |
| Isselbacher, EM | 1 |
| Jaffer, FA | 1 |
| Lindsay, ME | 1 |
| Janssen, PM | 1 |
| Murray, JD | 1 |
| Schill, KE | 1 |
| Rastogi, N | 1 |
| Schultz, EJ | 1 |
| Tran, T | 1 |
| Raman, SV | 1 |
| Rafael-Fortney, JA | 1 |
| Kem, DC | 1 |
| Li, H | 1 |
| Velarde-Miranda, C | 1 |
| Liles, C | 1 |
| Vanderlinde-Wood, M | 1 |
| Galloway, A | 1 |
| Khan, M | 1 |
| Zillner, C | 1 |
| Benbrook, A | 1 |
| Rao, V | 1 |
| Gomez-Sanchez, CE | 1 |
| Cunningham, MW | 1 |
| Yu, X | 1 |
| Garg, K | 1 |
| Corona, BT | 1 |
| Walters, TJ | 1 |
| Spasov, AA | 1 |
| Yakovlev, DS | 1 |
| Bukatina, TM | 1 |
| Brigadirova, AA | 1 |
| Jankovic, SM | 1 |
| Stojadinovic, D | 1 |
| Stojadinovic, M | 1 |
| Jankovic, SV | 1 |
| Djuric, JM | 1 |
| Stojic, I | 1 |
| Kostic, M | 1 |
| Ziegler, MA | 1 |
| DiStasi, MR | 1 |
| Miller, SJ | 1 |
| Dalsing, MC | 1 |
| Unthank, JL | 1 |
| Patten, GS | 1 |
| Abeywardena, MY | 1 |
| Lemkens, P | 1 |
| Spijkers, LJ | 1 |
| Meens, MJ | 1 |
| Nelissen, J | 1 |
| Janssen, B | 1 |
| Peters, SL | 1 |
| Schiffers, PM | 1 |
| De Mey, JG | 1 |
| Boettger, T | 1 |
| Beetz, N | 1 |
| Kostin, S | 1 |
| Schneider, J | 1 |
| Krüger, M | 1 |
| Hein, L | 1 |
| Braun, T | 1 |
| Yang, HH | 1 |
| Kim, JM | 1 |
| Chum, E | 1 |
| van Breemen, C | 1 |
| Chung, AW | 1 |
| Matsumoto, T | 1 |
| Ishida, K | 1 |
| Taguchi, K | 1 |
| Kobayashi, T | 2 |
| Kamata, K | 1 |
| Vavrinec, P | 1 |
| van Dokkum, RP | 1 |
| Goris, M | 1 |
| Buikema, H | 2 |
| Henning, RH | 1 |
| Koba, S | 1 |
| Watanabe, R | 1 |
| Kano, N | 1 |
| Watanabe, T | 1 |
| de Godoy, MA | 3 |
| de Oliveira, AM | 4 |
| Wagenaar, LJ | 1 |
| Voors, AA | 1 |
| van Buiten, A | 1 |
| Lübeck, RH | 1 |
| Boonstra, PW | 1 |
| van Veldhuisen, DJ | 1 |
| van Gilst, WH | 1 |
| Santis, WF | 1 |
| Peters, CA | 1 |
| Yalla, SV | 2 |
| Sullivan, MP | 2 |
| Hakim, A | 1 |
| Stanke-Labesque, F | 2 |
| Hoffmann, P | 1 |
| Sessa, C | 2 |
| Caron, F | 1 |
| Cracowski, JL | 1 |
| Bessard, G | 2 |
| Pérez, NG | 1 |
| Villa-Abrille, MC | 1 |
| Aiello, EA | 1 |
| Dulce, RA | 1 |
| Cingolani, HE | 2 |
| Camilión de Hurtado, MC | 2 |
| Rattan, S | 3 |
| Miyamoto, A | 1 |
| Wada, R | 1 |
| Inoue, A | 1 |
| Ishiguro, S | 1 |
| Liao, JK | 1 |
| Nishio, A | 1 |
| McBride, TA | 1 |
| St-Louis, J | 1 |
| Sicotte, B | 1 |
| Beauséjour, A | 1 |
| Brochu, M | 1 |
| Castro-Chaves, P | 1 |
| Roncon-Albuquerque, R | 1 |
| Leite-Moreira, AF | 1 |
| Ewert, S | 1 |
| Spak, E | 1 |
| Olbers, T | 1 |
| Johnsson, E | 1 |
| Edebo, A | 1 |
| Fändriks, L | 1 |
| Alvarez, Y | 1 |
| Pérez-Girón, JV | 1 |
| Hernanz, R | 1 |
| Briones, AM | 1 |
| García-Redondo, A | 1 |
| Beltrán, A | 1 |
| Alonso, MJ | 1 |
| Salaices, M | 1 |
| Wang, Y | 1 |
| Wang, W | 1 |
| Wang, Q | 1 |
| Wu, J | 2 |
| Xu, J | 1 |
| Wu, X | 2 |
| Stebbins, CL | 1 |
| Bonigut, S | 1 |
| Yang, Z | 1 |
| Arnet, U | 1 |
| von Segesser, L | 1 |
| Siebenmann, R | 1 |
| Turina, M | 1 |
| Lüscher, TF | 1 |
| Nally, JE | 1 |
| Clayton, RA | 1 |
| Wakelam, MJ | 1 |
| Thomson, NC | 1 |
| McGrath, JC | 1 |
| Dickinson, KE | 1 |
| Cohen, RB | 1 |
| Skwish, S | 1 |
| Delaney, CL | 1 |
| Serafino, RP | 1 |
| Poss, MA | 1 |
| Gu, Z | 1 |
| Ryono, DE | 1 |
| Moreland, S | 1 |
| Powell, JR | 1 |
| Hopkins, BJ | 1 |
| Hodgson, WC | 1 |
| Sutherland, SK | 1 |
| Nishimura, H | 1 |
| Walker, OE | 1 |
| Patton, CM | 1 |
| Madison, AB | 1 |
| Chiu, AT | 1 |
| Keiser, J | 1 |
| Zhang, JS | 2 |
| van Meel, JC | 2 |
| Pfaffendorf, M | 3 |
| van Zwieten, PA | 3 |
| Zhang, J | 1 |
| Burns, L | 1 |
| Clark, KL | 3 |
| Bradley, J | 1 |
| Robertson, MJ | 3 |
| Clark, AJ | 1 |
| Wragg, A | 1 |
| Liu, YJ | 2 |
| Shibouta, Y | 1 |
| Inada, Y | 2 |
| Ojima, M | 2 |
| Wada, T | 1 |
| Noda, M | 1 |
| Sanada, T | 1 |
| Kubo, K | 2 |
| Kohara, Y | 2 |
| Naka, T | 2 |
| Nishikawa, K | 2 |
| Tanabe, N | 1 |
| Ueno, A | 1 |
| Tsujimoto, G | 1 |
| Okunishi, H | 1 |
| Song, K | 1 |
| Oka, Y | 1 |
| Kawamoto, T | 1 |
| Ishihara, H | 1 |
| Mori, N | 1 |
| Miyazaki, M | 1 |
| Hawcock, AB | 1 |
| Barnes, JC | 2 |
| Hegde, SS | 1 |
| Clarke, DE | 1 |
| Sugiura, Y | 1 |
| Itoh, K | 1 |
| Furukawa, Y | 1 |
| Sim, MK | 1 |
| Soh, KS | 1 |
| Sum, CS | 2 |
| Cheung, WT | 2 |
| Peral de Bruno, M | 1 |
| Coviello, A | 1 |
| Wan, DC | 1 |
| Alvarez-Guerra, M | 1 |
| Alda, O | 1 |
| Morin, E | 1 |
| Allard, M | 1 |
| Garay, RP | 1 |
| Persson, K | 1 |
| Pandita, RK | 1 |
| Waldeck, K | 1 |
| Andersson, KE | 1 |
| Travo, P | 1 |
| Lees, D | 1 |
| Benel, L | 1 |
| Miyazawa, K | 1 |
| Fukuyama, J | 1 |
| Misawa, K | 1 |
| Hamano, S | 1 |
| Ujiie, A | 1 |
| Li, Q | 1 |
| Feenstra, M | 1 |
| Eijsman, L | 1 |
| Li, P | 1 |
| Ferrario, CM | 1 |
| Brosnihan, KB | 1 |
| Lee, BH | 2 |
| Shin, HS | 2 |
| Li, JS | 2 |
| Sharifi, AM | 1 |
| Schiffrin, EL | 2 |
| Tamura, K | 1 |
| Okuhira, M | 1 |
| Mikoshiba, I | 1 |
| Hashimoto, K | 1 |
| Comiter, CV | 1 |
| Kifor, I | 1 |
| le Tran, Y | 1 |
| Forster, C | 1 |
| Hong, KW | 1 |
| Kim, CD | 1 |
| Lee, SH | 2 |
| Yoo, SE | 2 |
| Fisslthaler, B | 1 |
| Schini-Kerth, VB | 1 |
| Fleming, I | 1 |
| Busse, R | 1 |
| Alvarez, BV | 1 |
| Ennis, IL | 1 |
| Holmgren, A | 1 |
| Pantev, E | 1 |
| Erlinge, D | 1 |
| Edvinsson, L | 1 |
| Touyz, RM | 1 |
| Endemann, D | 1 |
| He, G | 1 |
| Jung, YS | 1 |
| Yun, SI | 1 |
| Shimuta, SI | 1 |
| Borges, AC | 1 |
| Prioste, RN | 1 |
| Paiva, TB | 2 |
| Kähönen, M | 1 |
| Tolvanen, JP | 1 |
| Kalliovalkama, J | 1 |
| Karjala, K | 1 |
| Mäkynen, H | 1 |
| Pörsti, I | 1 |
| Morsing, P | 1 |
| Adler, G | 1 |
| Brandt-Eliasson, U | 1 |
| Karp, L | 1 |
| Ohlson, K | 1 |
| Renberg, L | 1 |
| Sjöquist, PO | 1 |
| Abrahamsson, T | 1 |
| Pape, D | 1 |
| Goineau, S | 1 |
| Guillo, P | 1 |
| Durand-Castel, X | 1 |
| Bellissant, E | 1 |
| McMullen, JR | 1 |
| Gibson, KJ | 1 |
| Lumbers, ER | 1 |
| Burrell, JH | 1 |
| Tripodi, F | 1 |
| Devillier, P | 1 |
| Chavanon, O | 1 |
| Tong, YC | 1 |
| Wang, CJ | 1 |
| Chan, P | 1 |
| Cheng, JT | 1 |
| Park, JK | 1 |
| Kim, SZ | 1 |
| Kim, SH | 1 |
| Kim, YG | 1 |
| Cho, KW | 1 |
| Crespo, MJ | 1 |
| Fujinaka, H | 1 |
| Miyazaki, Y | 1 |
| Matsusaka, T | 1 |
| Yoshida, H | 1 |
| Fogo, AB | 1 |
| Inagami, T | 1 |
| Ichikawa, I | 1 |
| Accorsi-Mendonça, D | 2 |
| Corrêa, FM | 2 |
| Anselmo-Franci, JA | 2 |
| Fan, YP | 1 |
| Puri, RN | 1 |
| Drew, GM | 1 |
| Marshall, FH | 1 |
| Michel, A | 1 |
| Middlemiss, D | 1 |
| Ross, BC | 1 |
| Scopes, D | 1 |
| Dowle, MD | 1 |
| Wienen, W | 1 |
| Mauz, AB | 1 |
| Entzeroth, M | 1 |
| Wong, PC | 1 |
| Tam, SW | 1 |
| Herblin, WF | 1 |
| Timmermans, PB | 1 |
| Dudley, DT | 1 |
| Panek, RL | 1 |
| Major, TC | 1 |
| Lu, GH | 1 |
| Bruns, RF | 1 |
| Klinkefus, BA | 1 |
| Weishaar, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319] | Phase 1 | 2 participants (Actual) | Interventional | 2018-12-05 | Terminated (stopped due to Inability to recruit participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months
| Intervention | sec (Number) |
|---|---|
| Spironolactone | -0.6 |
| Prednisolone | -5.3 |
Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months
| Intervention | kg (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elbow Flexion (Right)-Baseline | Elbow Flexion (Left)-Baseline | Elbow Extension (Right)-Baseline | Elbow Extension (Left)-Baseline | Knee Flexion (Right)-Baseline | Knee Flexion (Left)-Baseline | Knee Extension (Right)-Baseline | Knee Extension (Left)-Baseline | Elbow Flexion (Right)-Month 6 | Elbow Flexion (Left)-Month 6 | Elbow Extension (Right)-Month 6 | Elbow Extension (Left)-Month 6 | Knee Flexion (Right)-Month 6 | Knee Flexion (Left)-Month 6 | Knee Extension (Right)-Month 6 | Knee Extension (Left)-Month 6 | |
| Prednisolone | 3.6 | 4.1 | 5.3 | 4.1 | 3.3 | 3.4 | 4.8 | 5.2 | 2.9 | 3.4 | 4.3 | 3.8 | 4.1 | 3.9 | 6 | 5.1 |
| Spironolactone | 0 | 0 | 0 | 0 | 4.1 | 2.8 | 3.8 | 5.9 | 3.1 | 3.5 | 2.4 | 2.5 | 4.3 | 4.1 | 7.2 | 8.3 |
Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months
| Intervention | mmol/L (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium-Baseline | Sodium-Month 1 | Sodium-Month 2 | Sodium-Month 3 | Sodium-Month 4 | Sodium-Month 5 | Sodium-Month 6 | Potassium-Baseline | Potassium-Month 1 | Potassium-Month 2 | Potassium-Month 3 | Potassium-Month 4 | Potassium-Month 5 | Potassium-Month 6 | Chloride-Baseline | Chloride-Month 1 | Chloride-Month 2 | Chloride-Month 3 | Chloride-Month 4 | Chloride-Month 5 | Chloride-Month 6 | CO2-Baseline | CO2-Month 1 | CO2-Month 2 | CO2-Month 3 | CO2-Month 4 | CO2-Month 5 | CO2-Month 6 | |
| Prednisolone | 140 | 140 | 139 | 141 | 139 | 139 | 143 | 3.8 | 4 | 4.5 | 3.9 | 4.6 | 4.2 | 3.9 | 105 | 105 | 104 | 105 | 105 | 106 | 105 | 22 | 24 | 24 | 24 | 25 | 26 | 26 |
| Spironolactone | 142 | 142 | 141 | 142 | 139 | 139 | 140 | 4.5 | 4.7 | 4.2 | 4.1 | 4.5 | 4.5 | 4.3 | 103 | 109 | 107 | 103 | 103 | 103 | 101 | 29 | 22 | 25 | 27 | 28 | 28 | 26 |
91 other studies available for losartan and Muscle Contraction
| Article | Year |
|---|---|
Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Biphenyl Compounds; Cell | 1991 |
4-(Heteroarylthio)-2-biphenylyltetrazoles as nonpeptide angiotensin II antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Abdominal; Binding, Competitive; B | 1995 |
Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoro
Topics: Angiotensin Receptor Antagonists; Animals; Aorta; Disease Models, Animal; GABA Antagonists; gamma-Am | 1993 |
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Biologica | 1993 |
Design, synthesis, and biological activities of four angiotensin II receptor ligands with gamma-turn mimetics replacing amino acid residues 3-5.
Topics: Angiotensin II; Animals; Aorta; Disulfides; In Vitro Techniques; Ligands; Magnetic Resonance Spectro | 1997 |
Differential expression of angiotensin II type 1 receptor subtypes within the cerebral microvasculature.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Cerebrovascular Circulation; Gene Expr | 2020 |
Effects of losartan on vasomotor function and canonical transient receptor potential channels in the aortas of sinoaortic denervation rats.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Denervation; Endot | 2018 |
Inhibition of the methyltranferase EZH2 improves aortic performance in experimental thoracic aortic aneurysm.
Topics: Animals; Aorta, Thoracic; Aortic Aneurysm, Thoracic; Disease Models, Animal; DNA Methylation; Enhanc | 2018 |
Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Diuretics; Dystrophin; Female; Gene Expression; | 2014 |
Autoimmune mechanisms activating the angiotensin AT1 receptor in 'primary' aldosteronism.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Autoantibodies; Autoimmun | 2014 |
Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Dose-Response Relationship | 2014 |
In vitro method of studying the angiotensin activity of chemical compounds.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Drug Evaluation, Preclinical; Female; In Vitro Tec | 2014 |
Angiotensin Receptor Blocker Losartan Inhibits Spontaneous Motility of Isolated Human Ureter.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2016 |
Novel method to assess arterial insufficiency in rodent hind limb.
Topics: Animals; Feasibility Studies; Femoral Artery; Femoral Vein; Hindlimb; Hyperemia; Ligation; Losartan; | 2016 |
Effects of Antihypertensive Agents on Intestinal Contractility in the Spontaneously Hypertensive Rat: Angiotensin Receptor System Downregulation by Losartan.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Colon; Down-Regulation; Ileum; Intestines; Losarta | 2017 |
Dual NEP/ECE inhibition improves endothelial function in mesenteric resistance arteries of 32-week-old SHR.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzazepines; Bosentan; Endothelin-Converting Enzy | 2017 |
Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Arteries | 2009 |
Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Aortic Aneurysm, Tho | 2009 |
Short-term angiotensin-1 receptor antagonism in type 2 diabetic Goto-Kakizaki rats normalizes endothelin-1-induced mesenteric artery contraction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Endothel | 2010 |
Losartan protects mesenteric arteries from ROS-associated decrease in myogenic constriction following 5/6 nephrectomy.
Topics: Acetylcholine; Animals; Blood Pressure; Endothelium, Vascular; Free Radical Scavengers; In Vitro Tec | 2011 |
Oxidative stress exaggerates skeletal muscle contraction-evoked reflex sympathoexcitation in rats with hypertension induced by angiotensin II.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Afferent Pathways; Angiotensin II; Angiotens | 2013 |
Cross-talk between AT(1) and AT(2) angiotensin receptors in rat anococcygeus smooth muscle.
Topics: Angiotensin II; Animals; Imidazoles; Kinetics; Losartan; Male; Muscle Contraction; Muscle, Smooth; N | 2002 |
Functional antagonism of different angiotensin II type I receptor blockers in human arteries.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Dose-Response | 2002 |
Ureteral function is modulated by a local renin-angiotensin system.
Topics: Adult; Angiotensin II; Animals; Electric Stimulation; Humans; Immunohistochemistry; In Vitro Techniq | 2003 |
Functional comparison of the antagonistic properties of some Angiotensin II type 1 receptor blockers on the contraction elicited by Angiotensin II and thromboxane A2 on human saphenous veins.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin II; Angiotensin II T | 2003 |
A low dose of angiotensin II increases inotropism through activation of reverse Na(+)/Ca(2+) exchange by endothelin release.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cats; Electrophysiology; Endotheli | 2003 |
Angiotensin II-induced relaxation of anococcygeus smooth muscle via desensitization of AT1 receptor, and activation of AT2 receptor associated with nitric-oxide synthase pathway.
Topics: Adenine; Angiotensin II; Animals; Blotting, Western; CD13 Antigens; Drug Interactions; Glutamyl Amin | 2004 |
Role of angiotensin II receptor subtypes in porcine basilar artery: functional, radioligand binding, and cell culture studies.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin Recept | 2006 |
AT1 receptors are necessary for eccentric training-induced hypertrophy and strength gains in rat skeletal muscle.
Topics: Adaptation, Physiological; Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relations | 2006 |
Remodeling and angiotensin II responses of the uterine arcuate arteries of pregnant rats are altered by low- and high-sodium intake.
Topics: Aldosterone; Angiotensin II; Animals; Arteries; Dose-Response Relationship, Drug; Female; Losartan; | 2006 |
Angiotensin-converting enzyme and angiotensin II receptor subtype 1 inhibitors restitute hypertensive internal anal sphincter in the spontaneously hypertensive rats.
Topics: Anal Canal; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2006 |
Endothelin ETA receptors and endothelium partially mediate the positive inotropic and lusitropic effects of angiotensin II.
Topics: Angiotensin II; Animals; Dose-Response Relationship, Drug; Endothelium; Losartan; Muscle Contraction | 2006 |
Angiotensin II induced contraction of rat and human small intestinal wall musculature in vitro.
Topics: Adrenergic Antagonists; Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiot | 2006 |
Losartan reduces the increased participation of cyclooxygenase-2-derived products in vascular responses of hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxidants; Blotting, W | 2007 |
[Ca2+]i and PKC-alpha are involved in the inhibitory effects of Ib, a novel nonpeptide AngiotensinII subtype AT1 receptor antagonist, on AngiotensinII-induced vascular contraction in vitro.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Calcium; Losartan | 2007 |
Spinal angiotensin II influences reflex cardiovascular responses to muscle contraction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Physio | 1995 |
Different effects of angiotensin-converting enzyme inhibition in human arteries and veins.
Topics: Acetylcholine; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Com | 1993 |
Angiotensin II enhances responses to endothelin-1 in bovine bronchial smooth muscle.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Azepines; Biphen | 1994 |
BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.
Topics: Adrenal Cortex; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypert | 1994 |
Pharmacological studies of stonefish (Synanceja trachynis) venom.
Topics: Animals; Biphenyl Compounds; Blood Pressure; Captopril; Chromones; Dose-Response Relationship, Drug; | 1994 |
Novel angiotensin receptor subtypes in fowl.
Topics: Acetylcholine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Abdominal; Biphenyl | 1994 |
Inhibitory effect of dithiothreitol on angiotensin II-induced contractions mediated by AT1-receptors in rat portal vein and rabbit aorta.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Benzimidazoles; Binding Sites; Bip | 1994 |
A non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Dose-Response Relatio | 1994 |
Molecular cloning of the canine angiotensin II receptor. An AT1-like receptor with reduced affinity for DuP753.
Topics: Amino Acid Sequence; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Base Sequence | 1994 |
Modulation of tachyphylaxis to angiotensin II in rabbit isolated aorta by the angiotensin AT1 receptor antagonist, losartan.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Biphenyl Compounds; Drug | 1994 |
Antagonist effect of losartan on angiotensin II induced contraction in five isolated smooth muscle assays.
Topics: Angiotensin II; Animals; Aorta; Biphenyl Compounds; Guinea Pigs; Ileum; Imidazoles; In Vitro Techniq | 1993 |
Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethy
Topics: Adrenal Cortex; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihype | 1993 |
Angiotensin II receptors in the rat urinary bladder smooth muscle: type 1 subtype receptors mediate contractile responses.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Binding, Competitive; Biphenyl Compounds; | 1993 |
In vitro pharmacology of a novel non-peptide angiotensin II-receptor antagonist, E4177.
Topics: Adrenal Cortex; Adrenal Glands; Adrenal Medulla; Angiotensin II; Angiotensin Receptor Antagonists; A | 1993 |
Pharmacological characterization of the contractile responses to angiotensin analogues in guinea-pig isolated longitudinal muscle of small intestine.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atropine; Biphenyl Compounds; Guinea Pigs | 1993 |
Characterization of angiotensin receptors mediating the neuromodulatory effects of angiotensin in the vas deferens of the rabbit.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Interactions; El | 1993 |
Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazoles.
Topics: Adrenal Cortex; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Benzimidazoles; Bi | 1993 |
Evidence that [Sar1]angiotensin II behaves differently from angiotensin II at angiotensin AT1 receptors in rabbit aorta.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Binding Sites; Biphenyl Compounds; | 1993 |
Effects of des-Asp-angiotensin I on the electrically stimulated contraction of the rabbit pulmonary artery.
Topics: Angiotensin I; Animals; Antihypertensive Agents; Biphenyl Compounds; Electric Stimulation; Imidazole | 1995 |
Characterization of contractile response to angiotensin in epididymal rat vas deferens.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; B | 1995 |
Effects of angiotensin II antagonists on the contractile and hydrosmotic effect of AT II and AT III in the toad (Bufo arenarum).
Topics: Analysis of Variance; Angiotensin II; Angiotensin III; Animals; Antihypertensive Agents; Aorta; Biph | 1996 |
Potentiation of purinergic transmission by angiotensin in prostatic rat vas deferens.
Topics: Adrenergic Uptake Inhibitors; Angiotensin I; Angiotensin II; Animals; Biphenyl Compounds; Electric S | 1996 |
Reduction by (-)-cicletanine of the vascular reactivity to angiotensin II in rats.
Topics: Administration, Oral; Angiotensin II; Animals; Antihypertensive Agents; Aorta, Thoracic; Biphenyl Co | 1996 |
Angiotensin II and bladder obstruction in the rat: influence on hypertrophic growth and contractility.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Female; Hypertrophy; | 1996 |
An hypothesis for the interpretation of the contractile response of vascular smooth muscle at the cellular level.
Topics: Angiotensin II; Animals; Anti-Arrhythmia Agents; Aorta, Thoracic; Biphenyl Compounds; Cells, Culture | 1996 |
Tranilast antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Anticoagulants; Antihypertensive Agents; | 1996 |
Comparative vasoconstrictor effects of angiotensin II, III, and IV in human isolated saphenous vein.
Topics: Aged; Aged, 80 and over; Aminopeptidases; Angiotensin II; Angiotensin III; Angiotensin Receptor Anta | 1997 |
Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Coronary Vessels; Dogs; Dose-Response Relation | 1997 |
Interaction of nitric oxide and the renin angiotensin system in renal hypertensive rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Enzyme Inhibit | 1997 |
Effect of AT1 angiotensin-receptor blockade on structure and function of small arteries in SHR.
Topics: Angiotensin Receptor Antagonists; Animals; Aorta; Arteries; Biphenyl Compounds; Blood Pressure; Coro | 1997 |
In vitro pharmacological properties of KRH-594, a novel angiotensin II type 1 receptor antagonist.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Guinea Pi | 1997 |
Effect of angiotensin II on corpus cavernosum smooth muscle in relation to nitric oxide environment: in vitro studies in canines.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Dogs; Electric Stimulation; Enzyme Inhibi | 1997 |
Angiotensin-(1-7) and the rat aorta: modulation by the endothelium.
Topics: Angiotensin I; Angiotensin II; Angiotensin III; Animals; Antihypertensive Agents; Aorta, Thoracic; D | 1997 |
The in vitro pharmacological profile of KR31080, a nonpeptide AT1 receptor antagonist.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Angiotensin II; Angiotensin Receptor Antagonists; Animals; | 1998 |
Thrombin receptor expression is increased by angiotensin II in cultured and native vascular smooth muscle cells.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihyperte | 1998 |
Stretch-induced alkalinization of feline papillary muscle: an autocrine-paracrine system.
Topics: Alkalies; Alkaloids; Amiloride; Angiotensin II; Animals; Anti-Arrhythmia Agents; Autocrine Communica | 1998 |
Inhibition of angiotensin II-induced contraction by losartan in human coronary arteries.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Coronary Vessels; Dose-Re | 1998 |
Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR.
Topics: Aging; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Hypertension; Imid | 1999 |
Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; | 1999 |
Different pathways for Ca2+ mobilization by angiotensin II and carbachol in the circular muscle of the guinea-pig ileum.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Calcium; Calcium Channel Blockers; Carbac | 1999 |
Losartan and enalapril therapies enhance vasodilatation in the mesenteric artery of spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Diclofenac; Enalapril; Endothelium; E | 1999 |
Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Benzimida | 1999 |
Endothelin, but not angiotensin II, contributes to the hypoxic contractile response of large isolated pulmonary arteries in the rat.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1999 |
Interactions between AT1 and AT2 receptors in uterine arteries from pregnant ewes.
Topics: Angiotensin I; Angiotensin II; Animals; Anti-Arrhythmia Agents; Arteries; Female; Hypersensitivity; | 1999 |
Antagonistic effects of losartan on thromboxane A2-receptors in human isolated gastroepiploic artery and saphenous vein.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin II; Angiotensin Rece | 1999 |
Effect of N-(biphenylyl-methyl)imidazole, a type 1 angiotensin II receptor inhibitor, on the contractile function of the rat corpus cavernosum.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Losartan; Male; | 2000 |
Renin angiotensin system of rabbit clitoral cavernosum: interaction with nitric oxide.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Clitoris; Culture Techniqu | 2000 |
Interaction between AT1 and alpha1-adrenergic receptors in cardiomyopathic hamsters.
Topics: Angiotensin I; Animals; Antihypertensive Agents; Aorta; Cardiomyopathies; Cricetinae; Disease Models | 2000 |
Salutary role for angiotensin in partial urinary tract obstruction.
Topics: Angiotensin II; Animals; Kidney; Losartan; Male; Muscle Contraction; Muscle, Smooth; Pelvis; Perista | 2000 |
Influence of estrogen and/or progesterone on isolated ovariectomized rat uterus. Responsiveness to Ang II.
Topics: Angiotensin II; Animals; Dose-Response Relationship, Drug; Estrogens; Female; Imidazoles; In Vitro T | 2002 |
Comparison of angiotensin II (Ang II) effects in the internal anal sphincter (IAS) and lower esophageal sphincter smooth muscles.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Anal Canal; Angiotensin II; Animals; Dose-Response Re | 2002 |
Angiotensin actions on the isolated rat uterus during the estrous cycle: influence of resting membrane potential and uterine morphology.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Dose-Response Relationship, Drug; Estrous | 2002 |
Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Binding Sites; Biphenyl Compounds; | 1992 |
Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Binding Sites; Biphenyl | 1992 |
Further studies on the selectivity of DuP 753, a nonpeptide angiotensin II receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Brain; Guinea Pigs; Ileum; Imidazoles; In | 1991 |
Subclasses of angiotensin II binding sites and their functional significance.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Binding Sites; Blood Pressure; Female; Gu | 1990 |